CN103648517B - 神经保护肽 - Google Patents

神经保护肽 Download PDF

Info

Publication number
CN103648517B
CN103648517B CN201280014793.1A CN201280014793A CN103648517B CN 103648517 B CN103648517 B CN 103648517B CN 201280014793 A CN201280014793 A CN 201280014793A CN 103648517 B CN103648517 B CN 103648517B
Authority
CN
China
Prior art keywords
peptide
amino acid
peptides
amino acids
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280014793.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103648517A (zh
Inventor
E·皮纳
N·齐萨佩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurim Pharmaceuticals 1991 Ltd
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of CN103648517A publication Critical patent/CN103648517A/zh
Application granted granted Critical
Publication of CN103648517B publication Critical patent/CN103648517B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201280014793.1A 2011-03-24 2012-03-22 神经保护肽 Active CN103648517B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161466966P 2011-03-24 2011-03-24
US61/466,966 2011-03-24
PCT/IL2012/050104 WO2012127475A1 (en) 2011-03-24 2012-03-22 Neuroprotective peptides

Publications (2)

Publication Number Publication Date
CN103648517A CN103648517A (zh) 2014-03-19
CN103648517B true CN103648517B (zh) 2016-04-20

Family

ID=45999925

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280014793.1A Active CN103648517B (zh) 2011-03-24 2012-03-22 神经保护肽

Country Status (13)

Country Link
US (1) US20140045764A1 (OSRAM)
EP (1) EP2688582B1 (OSRAM)
JP (1) JP5960793B2 (OSRAM)
KR (1) KR20140036164A (OSRAM)
CN (1) CN103648517B (OSRAM)
AU (1) AU2012232642B2 (OSRAM)
BR (1) BR112013024323A2 (OSRAM)
CA (1) CA2830792A1 (OSRAM)
EA (1) EA201391387A1 (OSRAM)
MX (1) MX2013010910A (OSRAM)
SG (1) SG193418A1 (OSRAM)
WO (1) WO2012127475A1 (OSRAM)
ZA (1) ZA201307169B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220899D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived pegylated peptides
WO2017131468A1 (ko) * 2016-01-27 2017-08-03 경상대학교산학협력단 아디포넥틴 수용체 활성화 신규 펩티드를 유효성분으로 포함하는 신경질환의 예방, 개선 또는 치료용 조성물
EP3438120A4 (en) * 2016-03-31 2019-12-04 Senju Pharmaceutical Co., Ltd. NEUROPROTECTIVE PEPTIDE
JP6962908B2 (ja) * 2016-03-31 2021-11-05 千寿製薬株式会社 神経保護ペプチド
CN111344300B (zh) 2017-11-14 2024-08-30 千寿制药株式会社 Pacap的稳定化肽
CN113271890B (zh) 2018-11-08 2024-08-30 内奥瓦斯克迪亚拉公司 经导管二尖瓣假体的心室展开
PL3974027T3 (pl) 2019-05-14 2025-02-24 Senju Pharmaceutical Co., Ltd. Stabilizowany peptyd pacap
US20220202905A1 (en) 2019-05-14 2022-06-30 Senju Pharmaceutical Co., Ltd. Composition for preventing or treating neurotrophic keratitis which contains pacap peptide or stabilized pacap peptide
CN112569351B (zh) * 2020-12-16 2021-10-15 南通大学 Cd44抗体在制备治疗帕金森疾病的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101821407A (zh) * 2007-07-10 2010-09-01 纽瑞姆制药（1991）有限公司 神经退行性疾病中的cd44剪接变体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2165461A1 (en) * 1993-06-18 1995-01-05 Sirpa Jalkanen Compositions and diagnostic methods using monoclonal antibodies against cd44v6
AU689226B2 (en) * 1994-01-18 1998-03-26 President And Fellows Of Harvard College CD44 expression in smooth muscle cells
DE19653607A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
WO1999037317A1 (en) * 1998-01-24 1999-07-29 Bristol-Myers Squibb Company Artificial proteoglycans
EP1647556B1 (en) * 2004-10-14 2010-05-19 Karlsruher Institut für Technologie Peptidic compounds and derivatives thereof for the treatment of human diseases through inhibition of signaling via growth factors
EP2266593A1 (en) * 2009-06-24 2010-12-29 Karlsruher Institut für Technologie Use of CD44v6 in the treatment of ophthalmic diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101821407A (zh) * 2007-07-10 2010-09-01 纽瑞姆制药（1991）有限公司 神经退行性疾病中的cd44剪接变体

Also Published As

Publication number Publication date
AU2012232642B2 (en) 2016-12-08
WO2012127475A1 (en) 2012-09-27
US20140045764A1 (en) 2014-02-13
EA201391387A1 (ru) 2014-01-30
KR20140036164A (ko) 2014-03-25
AU2012232642A1 (en) 2013-10-17
BR112013024323A2 (pt) 2017-06-13
ZA201307169B (en) 2014-05-28
CA2830792A1 (en) 2012-09-27
SG193418A1 (en) 2013-10-30
JP5960793B2 (ja) 2016-08-02
EP2688582B1 (en) 2017-02-15
JP2014510101A (ja) 2014-04-24
CN103648517A (zh) 2014-03-19
MX2013010910A (es) 2014-03-27
EP2688582A1 (en) 2014-01-29

Similar Documents

Publication Publication Date Title
CN103648517B (zh) 神经保护肽
ES2439950T3 (es) Péptidos con permeabilidad celular inhibidores de la ruta de transducción de señales de la JNK
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
CN102498127B (zh) 用于治疗氧化应激相关障碍的肽类
JP2025120320A (ja) Ｖｉｐｒ２アンタゴニストペプチド
EP3313428A1 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment
EP1856145A2 (en) Voltage dependent anion channel (vdac1) compositions and methods of use thereof for regulating apoptosis
KR102084341B1 (ko) 짧은 합성 펩티드 및 그의 용도
WO2008050133A2 (en) Inhibition of beta-amyloid aggregation
CN107106643A (zh) 在癌症或癌转移的治疗或预防中的环状乙酰胆碱酯酶c端肽
US20230391841A1 (en) Macrocyclic peptides
WO2021100041A1 (en) Treating alzheimer's disease
JPWO2017170924A1 (ja) 神経保護ペプチド
CA3183431A1 (en) Means and methods for the treatment of pathological aggregation
US20230095144A1 (en) Amyloid inhibitory peptides
NZ535623A (en) Peptides, 4-14 amino acids in length, for treating degenerative conditions of the CNS
KR20140084191A (ko) 멜라노트란스페린으로부터 유도된 펩티드 화합물 및 이의 용도
WO2014161095A1 (en) Crp40 fragments for the treatment of neurological disorders
JPWO2017170926A1 (ja) 神経保護ペプチド

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant